Empirical Antifungal Treatment of Critically Ill Patients With Influenza-Associated Acute Respiratory Distress Syndrome: A Bayesian Perspective.

IF 8.3 1区医学 Q1 IMMUNOLOGY

Clinical Infectious Diseases Pub Date : 2026-10-17 DOI:10.1093/cid/ciag662

Caroline Wilhelmer, Lisa Kriegl, Robert Krause, Stefan Hatzl

引用次数: 0

Abstract

We reanalyzed 172 critically ill patients with influenza-associated ARDS in a Bayesian framework. Empirical mold-active antifungal treatment yielded a posterior median hazard ratio for influenza-associated pulmonary aspergillosis of 0.51 (95% credible interval 0.20-1.17; probability of benefit 94%), without mortality benefit. Findings remained consistent across skeptical, non-informative and externally informed priors.

查看原文本刊更多论文

流感相关急性呼吸窘迫综合征危重患者经经性抗真菌治疗：贝叶斯视角

我们在贝叶斯框架下重新分析了172例流感相关急性呼吸窘迫综合征危重患者。经验性霉菌活性抗真菌治疗对流感相关肺曲霉病的后中位风险比为0.51(95%可信区间0.20-1.17；获益概率为94%)，无死亡率获益。研究结果在持怀疑态度的、非信息性的和外部知情的先验中保持一致。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Infectious Diseases 医学-传染病学

CiteScore

25.00

自引率

2.50%

发文量

900

审稿时长

3 months

期刊介绍： Clinical Infectious Diseases (CID) is dedicated to publishing original research, reviews, guidelines, and perspectives with the potential to reshape clinical practice, providing clinicians with valuable insights for patient care. CID comprehensively addresses the clinical presentation, diagnosis, treatment, and prevention of a wide spectrum of infectious diseases. The journal places a high priority on the assessment of current and innovative treatments, microbiology, immunology, and policies, ensuring relevance to patient care in its commitment to advancing the field of infectious diseases.